Patterns and adherence to guidelines of antithrombotic therapy in thai patients with nonvalvular atrial fibrillation

Journal of the Medical Association of Thailand

Volumn 96, Issue 1, 2013, Pages 91-98

  Jedsadayanmata, Arom ^a  

^a NARESUAN UNIVERSITY   (Thailand)

Author keywords

Anticoagulation; Antithrombotics; Atrial fibrillation; Thromboembolism; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CILOSTAZOL; CLOPIDOGREL; DIPYRIDAMOLE; TICLOPIDINE; WARFARIN;

ADULT; AGED; AMBULATORY CARE; ARTICLE; BRAIN ISCHEMIA; CHADS2 SCORE; COMORBIDITY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; FEMALE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; NONVALVULAR ATRIAL FIBRILLATION; PRACTICE GUIDELINE; RISK FACTOR; THAILAND; THROMBOEMBOLISM; THYROTOXICOSIS;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; CROSS-SECTIONAL STUDIES; FEMALE; GUIDELINE ADHERENCE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; RISK FACTORS; STROKE; THAILAND; THROMBOEMBOLISM;

EID: 84873111282     PISSN: 01252208     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. 2011 ACCF/ AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2011; 123: e269-e367.
2. th Edition). Chest 2008; 133: 546S-592S.
3. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2369-2429.
4. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001; 285: 2864-2870.
5. Zimetbaum PJ, Thosani A, Yu HT, Xiong Y, Lin J, Kothawala P, et al. Are atrial fibrillation patients receiving warfarin in accordance with stroke risk? Am J Med 2010; 123: 446-453.
6. Nieuwlaat R, Capucci A, Lip G Y, Olsson SB, Prins MH, Nieman FH, et al. Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 2006; 27: 3018-3026.
7. Singh P, Arrevad PS, Peterson GM, Bereznicki LR. Evaluation of antithrombotic usage for atrial fibrillation in aged care facilities. J Clin Pharm Ther 2011; 36: 166-171.
8. Ogilvie IM, Newton N, Welner SA, Cowell W, Lip G Y. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med 2010; 123: 638-645.
9. Leung CS, Tam KM. Antithrombotic treatment of atrial fibrillation in a regional hospital in Hong Kong. Hong Kong Med J 2003; 9: 179-185.
10. Lin LJ, Cheng MH, Lee CH, Wung DC, Cheng CL, Kao Yang YH. Compliance with antithrombotic prescribing guidelines for patients with atrial fibrillation-a nationwide descriptive study in Taiwan. Clin Ther 2008; 30: 1726-1736.
11. Uchiyama S, Shibata Y, Hirabayashi T, Mihara B, Hamashige N, Kitagawa K, et al. Risk factor profiles of stroke, myocardial infarction, and atrial fibrillation: a Japanese Multicenter Cooperative Registry. J Stroke Cerebrovasc Dis 2010; 19: 190-197.
12. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857-867.
13. Meiltz A, Zimmermann M, Urban P, Bloch A. Atrial fibrillation management by practice cardiologists: a prospective survey on the adherence to guidelines in the real world. Europace 2008; 10: 674-680.
14. Vassilikos VP, Mantziari A, Goudis CA, Paraskevaidis S, Dakos G, Giannakoulas G, et al. Differences in management of atrial fibrillation between cardiologists and non-cardiologists in Greece. Hellenic J Cardiol 2010; 51: 113-121.
15. Choudhry NK, Anderson GM, Laupacis A, Ross-Degnan D, Normand SL, Soumerai SB. Impact of adverse events on prescribing warfarin in patients with atrial fibrillation: matched pair analysis. BMJ 2006; 332: 141-145.
16. Gattellari M, Worthington J, Zwar N, Middleton S. Barriers to the use of anticoagulation for nonvalvular atrial fibrillation: a representative survey of Australian family physicians. Stroke 2008; 39: 227-230.
17. Lip GY, Andreotti F, Fauchier L, Huber K, Hylek E, Knight E, et al. Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis. Europace 2011; 13: 723-746.
18. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138: 1093-1100.
19. Cairns JA, Connolly S, McMurtry S, Stephenson M, Talajic M. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter. Can J Cardiol 2011; 27: 74-90.
20. Go AS, Hylek EM, Borowsky LH, Phillips KA, Selby JV, Singer DE. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann Intern Med 1999; 131: 927-934.
21. Stafford RS, Singer DE. Recent national patterns of warfarin use in atrial fibrillation. Circulation 1998; 97: 1231-1233.
22. Gallagher AM, Rietbrock S, Plumb J, van Staa TP. Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: do the appropriate patients receive stroke prophylaxis? J Thromb Haemost 2008; 6: 1500-1506.
23. Frykman V, Beerman B, Ryden L, Rosenqvist M. Management of atrial fibrillation: discrepancy between guideline recommendations and actual practice exposes patients to risk for complications. Eur Heart J 2001; 22: 1954-1959.
24. Kalra L, Yu G, Perez I, Lakhani A, Donaldson N. Prospective cohort study to determine if trial efficacy of anticoagulation for stroke prevention in atrial fibrillation translates into clinical effectiveness. BMJ 2000; 320: 1236-1239.